Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Platelet microRNA expression and association with platelet maturity and function in patients with essential thrombocythemia.

Tran JQD, Pedersen OH, Larsen ML, Grove EL, Kristensen SD, Hvas AM, Nissen PH.

Platelets. 2019 Jun 26:1-8. doi: 10.1080/09537104.2019.1636019. [Epub ahead of print]

PMID:
31240987
2.

Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice.

Tran JQ, Muench MO, Heitman JW, Jackman RP.

Vox Sang. 2019 Apr;114(3):207-215. doi: 10.1111/vox.12756. Epub 2019 Feb 7.

PMID:
30734299
3.

Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.

Tran JQ, Hartung JP, Tompkins CA, Frohna PA.

Clin Pharmacol Drug Dev. 2018 Aug;7(6):634-640. doi: 10.1002/cpdd.409. Epub 2017 Nov 10.

4.

Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.

Tran JQ, Hartung JP, Olson AD, Mendzelevski B, Timony GA, Boehm MF, Peach RJ, Gujrathi S, Frohna PA.

Clin Pharmacol Drug Dev. 2018 Mar;7(3):263-276. doi: 10.1002/cpdd.383. Epub 2017 Aug 7.

5.

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.

Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, Brooks JL, Timony GA, Olson AD, Gujrathi S, Frohna PA.

J Clin Pharmacol. 2017 Aug;57(8):988-996. doi: 10.1002/jcph.887. Epub 2017 Apr 11.

6.

Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.

Diao L, Hang Y, Othman AA, Mehta D, Amaravadi L, Nestorov I, Tran JQ.

Br J Clin Pharmacol. 2016 Nov;82(5):1333-1342. doi: 10.1111/bcp.13051. Epub 2016 Aug 3.

7.

Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.

Tran JQ, Othman AA, Wolstencroft P, Elkins J.

Br J Clin Pharmacol. 2016 Jul;82(1):160-7. doi: 10.1111/bcp.12936. Epub 2016 May 4.

8.

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.

Tran JQ, Othman AA, Mikulskis A, Wolstencroft P, Elkins J.

Clin Pharmacol. 2016 Feb 11;8:9-13. doi: 10.2147/CPAA.S98221. eCollection 2016.

9.

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.

Diao L, Hang Y, Othman AA, Nestorov I, Tran JQ.

Clin Pharmacokinet. 2016 Aug;55(8):943-55. doi: 10.1007/s40262-016-0366-7.

PMID:
26873229
10.

Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.

Minocha M, Tran JQ, Sheridan JP, Othman AA.

Clin Pharmacokinet. 2016 Jan;55(1):121-30. doi: 10.1007/s40262-015-0305-z.

PMID:
26242380
11.

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033.

Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D.

Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18. doi: 10.1212/NXI.0000000000000018. eCollection 2014 Aug.

12.
13.

Heavy Metal Content in Thoracic Tissue Samples from Patients with and without NSCLC.

Tran JQ, Dranikov A, Iannucci A, Wagner WP, LoBello J, Allen J, Weiss GJ.

Lung Cancer Int. 2014;2014:853158. doi: 10.1155/2014/853158. Epub 2014 Jul 9.

14.

Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.

Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, Le Pogam S, Nájera I, Petric R, Tran JQ, Kulkarni R, Zhang Y, Smith P, Yetzer ES, Shulman NS.

Antimicrob Agents Chemother. 2014;58(2):1136-45. doi: 10.1128/AAC.01515-13. Epub 2013 Dec 2.

15.

Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.

Morcos PN, Chang L, Navarro M, Chung D, Smith PF, Brennan BJ, Tran JQ.

Int J Clin Pharmacol Ther. 2014 Feb;52(2):103-11. doi: 10.5414/CP201922.

PMID:
24290411
16.

Images in emergency medicine. Child with diarrhea and rash. Acrodermatitis enteropathica.

Chumpitazi CE, Tran JQ.

Ann Emerg Med. 2013 Oct;62(4):303, 318. doi: 10.1016/j.annemergmed.2013.01.020. No abstract available.

PMID:
24054094
17.

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.

Morcos PN, Chang L, Kulkarni R, Giraudon M, Shulman N, Brennan BJ, Smith PF, Tran JQ.

Eur J Clin Pharmacol. 2013 Nov;69(11):1939-49. doi: 10.1007/s00228-013-1556-y. Epub 2013 Jul 20.

PMID:
23872824
18.

A SAS-6-like protein suggests that the Toxoplasma conoid complex evolved from flagellar components.

de Leon JC, Scheumann N, Beatty W, Beck JR, Tran JQ, Yau C, Bradley PJ, Gull K, Wickstead B, Morrissette NS.

Eukaryot Cell. 2013 Jul;12(7):1009-19. doi: 10.1128/EC.00096-13. Epub 2013 May 17.

19.

Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.

Reddy MB, Chen Y, Haznedar JO, Fretland J, Blotner S, Smith P, Tran JQ.

Clin Pharmacokinet. 2012 Jul 1;51(7):457-65. doi: 10.2165/11599700-000000000-00000.

PMID:
22624502
20.

Transport of a solvent mixture across two glove materials when applied in a paint matrix.

Tran JQ, Ceballos DM, Dills RL, Yost MG, Morgan MS.

Arch Environ Contam Toxicol. 2012 Jul;63(1):169-76. doi: 10.1007/s00244-012-9758-3. Epub 2012 Mar 21.

PMID:
22434453
21.

SPM1 stabilizes subpellicular microtubules in Toxoplasma gondii.

Tran JQ, Li C, Chyan A, Chung L, Morrissette NS.

Eukaryot Cell. 2012 Feb;11(2):206-16. doi: 10.1128/EC.05161-11. Epub 2011 Oct 21.

22.

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.

Reddy MB, Connor A, Brennan BJ, Morcos PN, Zhou A, McLawhon P, Fretland A, Evans P, Smith P, Tran JQ.

Biopharm Drug Dispos. 2011 Jul;32(5):261-75. doi: 10.1002/bdd.756. Epub 2011 Jun 9.

PMID:
21660978
23.

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.

Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, Zhang Y, Sampeur P, Nájera I, Smith P, Shulman NS, Tran JQ.

J Hepatol. 2011 Nov;55(5):972-9. doi: 10.1016/j.jhep.2011.01.046. Epub 2011 Feb 24.

PMID:
21354234
24.

Case report: heavy metal burden presenting as Bartter syndrome.

Crinnion WJ, Tran JQ.

Altern Med Rev. 2010 Dec;15(4):303-10.

25.

RNG1 is a late marker of the apical polar ring in Toxoplasma gondii.

Tran JQ, de Leon JC, Li C, Huynh MH, Beatty W, Morrissette NS.

Cytoskeleton (Hoboken). 2010 Sep;67(9):586-98. doi: 10.1002/cm.20469.

26.

In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.

Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, Tran JQ.

Antimicrob Agents Chemother. 2005 Jun;49(6):2267-75.

27.

Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.

Tran JQ, Petersen C, Garrett M, Hee B, Kerr BM.

Clin Pharmacol Ther. 2002 Dec;72(6):615-26.

PMID:
12496743
28.

Delavirdine: clinical pharmacokinetics and drug interactions.

Tran JQ, Gerber JG, Kerr BM.

Clin Pharmacokinet. 2001;40(3):207-26. Review.

PMID:
11327199
29.
30.

Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.

Tran JQ, Di Cicco RA, Sheth SB, Tucci M, Peng L, Jorkasky DK, Hursting MJ, Benincosa LJ.

J Clin Pharmacol. 1999 May;39(5):513-9.

PMID:
10234600
31.

Supplemental Content

Support Center